Anglo-Swedish drugs giant AstraZeneca said on Thursday that its pre-tax profit in 2005 rose 34 percent compared with 2004 to reach 6.67 billion dollars (5.53 billion euros).
Sales were up 10 percent compared with the previous year at 23.95 billion dollars when adjusted for currency effects, the group said.
The results were slightly below analysts’ expectations and shares in the company fell in late morning trade.
At 11.11 GMT, the price of shares in AstraZeneca was showing a loss of 44 pence at 2,690 pence. Before publication of the figures, the shares had shown a loss of 37 pence at 2,697 pence.
AFP
Norway, which has suspended the use of AstraZeneca's Covid vaccine until further notice, will send 216,000 doses to Sweden and Iceland at their request, the Norwegian health ministry said Thursday.
“I’m happy that the vaccines we have in stock can be put to use even if the AstraZeneca vaccine has been paused in Norway,” Health Minister Bent Høie said in a statement.
The 216,000 doses, which are currently stored in Norwegian fridges, have to be used before their expiry dates in June and July.
Sweden will receive 200,000 shots and Iceland 16,000 under the expectation they will return the favour at some point.
“If we do resume the use of the AstraZeneca vaccine, we will get the doses back as soon as we ask,” Høie said.
Like neighbouring Denmark, Norway suspended the use of the AstraZeneca jab on March 11 in order to examine rare but potentially severe side effects, including blood clots.
Among the 134,000 AstraZeneca shots administered in Norway before the suspension, five cases of severe thrombosis, including three fatal ones, had been registered among relatively young people in otherwise good health. One other person died of a brain haemorrhage.
READ MORE: Norway delays final decision on withdrawal of AstraZeneca vaccine
The government has therefore set up a committee of Norwegian and international experts tasked with studying all of the risks linked to the AstraZeneca and Johnson & Johnson vaccines, which is also suspected of causing blood clots.
Both are both based on adenovirus vector technology. Denmark is the only European country to have dropped the AstraZeneca
vaccine from its vaccination campaign, and said on Tuesday it would “lend” 55,000 doses to the neighbouring German state of Schleswig-Holstein.
Please whitelist us to continue reading.
So this website can function correctly please whitelist The Local with your adblocker, antivirus software or browser add on.
Please visit the help centre for more information
